Anti-Human DPP3 Reference Antibody (Invobenitug, RUO) (HA918016)

Name: Anti-Human DPP3 Reference Antibody (Invobenitug, RUO)
Brand: abinScience
SKU: HA918016
Price: 370 USD
Availability: InStock

Price(USD):

Spec:

Number:

Get quote

Overview

Catalog No.	HA918016
Description	invobenitug (HA918016) is a research-grade recombinant antibody targeting DPP3. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research.
Species reactivity	Human
Applications	ELISA, FACS, Functional assay
Host species	Human
Isotype	IgG1, kappa
Target	DPP3
Endotoxin level	< 10 EU/mg
Purity	>95% as determined by SDS-PAGE
Accession	Q9NY33
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	CAS: 3034173-09-3
Background	Dipeptidyl peptidase 3 is a ~82 kDa protein. Cleaves and degrades bioactive peptides, including angiotensin, Leu-enkephalin and Met-enkephalin. Also cleaves Arg-Arg-beta-naphthylamide (in vitro). 1. Abramić, M. et al. (1992) Biological chemistry Hoppe-Seyler 373, 375-80. PMID: 1515063 2. Shimamori, Y. et al. (1988) Biochemical medicine and metabolic biology 40, 305-10. PMID: 3233187 3. Abramić, M. et al. (2000) Biological chemistry 381, 1233-43. PMID: 11209758 4. Fukasawa, K. et al. (1998) The Biochemical journal 329 ( Pt 2), 275-82. PMID: 9425109
Note	For research use only.

Images

References

Datasheet

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Overview